Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Net Income (2020 - 2025)

Historic Net Income for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to -$45.1 million.

  • Maravai Lifesciences Holdings' Net Income rose 7387.32% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.8 million, marking a year-over-year increase of 3391.36%. This contributed to the annual value of -$259.6 million for FY2024, which is 8762.2% down from last year.
  • Maravai Lifesciences Holdings' Net Income amounted to -$45.1 million in Q3 2025, which was up 7387.32% from -$69.8 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Net Income registered a high of $156.7 million during Q2 2022, and its lowest value of -$172.5 million during Q3 2024.
  • Its 5-year average for Net Income is $20.7 million, with a median of -$11.9 million in 2023.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Net Income surged by 922711.51% in 2021, and later crashed by 158249.26% in 2024.
  • Maravai Lifesciences Holdings' Net Income (Quarter) stood at $127.1 million in 2021, then plummeted by 31.22% to $87.4 million in 2022, then tumbled by 225.8% to -$110.0 million in 2023, then skyrocketed by 58.11% to -$46.1 million in 2024, then increased by 2.19% to -$45.1 million in 2025.
  • Its last three reported values are -$45.1 million in Q3 2025, -$69.8 million for Q2 2025, and -$52.9 million during Q1 2025.